본문바로가기
About Us
SK bioscience
Company Overview
History
Vision
Contact Us
Leadership
Message from the CEO
Headquarters & Facilities
SK bioscience Headquarters
R&D Center
L HOUSE
Subsidiary
SK bioscience USA
IDT Biologika
Science & Technology
Pipeline
R&D
Production
Business
Business Overview
Domestic
Overseas Business
Vaccine Co-Development
and Technology Transfer
CDMO/CMO
Products
In-house Products
Outsourced Products
Global Partnerships
ESG
새창열기 아이콘
IR
Corporate Governance
Company Information
Financial Information
Financial Statements
Financial Credit
Audit Reports
Investment Information
Stock Prices
Shareholder Status
IR Documents
Disclosure
PR
Press Releases
Media Zoom
Brochure
CI Guideline
sitemap
About Us
SK bioscience
Company Overview
History
Vision
Contact Us
Leadership
Message from the CEO
Headquarters & Facilities
SK bioscience Headquarters
R&D Center
L HOUSE
Subsidiary
SK bioscience USA
IDT Biologika
Science & Technology
Pipeline
R&D
Production
Business
Business Overview
Domestic
Overseas Business
Vaccine Co-Development
and Technology Transfer
CDMO/CMO
Products
In-house Products
Outsourced Products
Global Partnerships
ESG
IR
Corporate Governance
Company Information
Financial Information
Financial Statements
Financial Credit
Audit Reports
Investment Information
Stock Prices
Shareholder Status
IR Documents
Disclosure
PR
Press Releases
Media Zoom
Brochure
CI Guideline
사이트맵 닫기
Language
KOR
ENG
LinkedIn
YouTube
ESG
SK careers
C/S
SK ethics
Q
U
I
C
K
PR
SK bioscience company news updates
PR
About Us
Science & Technology
Business
ESG
IR
PR
Press Releases
Press Releases
Media Zoom
Brochure
CI Guideline
Press releases
SK Bioscience - Novavax-KDCA Sign Licensing Agreement and Purchase Agreement for Novavax´ COVID-19 Vaccine Candidate
2021 .02 .16
SK bioscience Submits Securities Report Aiming for KOSPI Listing by March
2021. 02. 08
SK bioscience Collaborates with GSK on COVID-19 Vaccine Development
2021. 02. 05
SK bioscience Signs Joint Sales Contract of Five Major Vaccines with GSK
2021. 01. 06
SK bioscience’s Typhoid Conjugate Vaccine Candidate Demonstrates Successful Phase III Clinical Trial Results
2020. 12. 17
SK bioscience’s COVID-19 Vaccine Candidate Is Chosen to First ‘Wave2’ Supporting Candidate
2020. 12. 10
SK bioscience-Seoul National University Hospital Agree Clinical Trial Cooperation for COVID-19 Vaccine ‘NBP2001’
2020. 12. 02
SK bioscience Announces Filing for KOSPI IPO
2020. 11. 30
SK bioscience’s COVID-19 Vaccine Candidate Enters Clinical Trial
2020. 11. 25
SK bioscience-Novavax Sign CDMO of COVID-19 Vaccine Agreement with Novavax
2020. 08. 14
처음
이전
11
12
13
다음
끝